Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
lactobacillus salivarius subsp. salicinius AP-32
- Development stage
- Preclinical
- Lead developer
- Bioflag Biotech
- Modality
- Synthetic Biology Platforms → Engineered Microbial Therapeutics → Microbiome Therapeutics, Fresh FMT → Fecal Microbiota Transplantation (FMT) → Microbiome Therapeutics, Yeast Strains → Single Strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Bacterial Strains → Single Strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Defined Consortia → Multi-strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Frozen FMT → Fecal Microbiota Transplantation (FMT) → Microbiome Therapeutics, Genetically Modified Bacteria → Engineered Microbial Therapeutics → Microbiome Therapeutics, Microbial Metabolites → Microbiome-Derived Products → Microbiome Therapeutics, Microbial Proteins → Microbiome-Derived Products → Microbiome Therapeutics, Complex Communities → Multi-strain Products → Live Biotherapeutic Products → Microbiome Therapeutics
- Administration
- Oral
01
Overview
Lactobacillus salivarius subsp. salicinius AP-32 is a specific probiotic strain isolated from healthy human intestines. It is being investigated for several therapeutic applications due to its ability to modulate the host's gut microbiome and immune system. [2] In preclinical studies on Parkinson's disease, AP-32 demonstrated neuroprotective effects, improved motor function, increased mitochondrial activity, and enhanced antioxidant levels. [4, 5, 14] It is also being studied for its efficacy in treating neonatal hyperbilirubinemia, where it has been shown in a clinical trial to reduce the duration of phototherapy and hospitalization. [6, 12] The proposed mechanisms of action include inhibiting intestinal β-glucuronidase, altering the profile of short-chain fatty acids (SCFAs), increasing antioxidant enzyme activities, and modulating the gut microbiota composition. [3, 4] Research has also explored its potential in managing blood glucose levels in diabetes and its anti-obesity effects. [10, 15] This strain is developed by Glac Biotech. [9, 13]
- Brand names
- Bioflag Lactobacillus salivarius AP-32
- Other names
- Ligilactobacillus salivarius AP-32L. salivarius subsp. salicinius AP-32
02
Targets
SLC5A1 (Sodium Glucose Cotransporter 1)SLC2A2 (Solute carrier family 2 facilitated glucose transporter member 2)GLUT5 (Glucose transporter 5)
Beyond the preview
Go deeper on lactobacillus salivarius subsp. salicinius AP-32.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on lactobacillus salivarius subsp. salicinius AP-32.